Identification of Potential Drug-related Problems in the Elderly: The Role of the Community Pharmacist

Vinks, Thijs H. A. M.; Koning, Fred H. P. De; Lange, Ton M. de; Egberts, Toine C. G.

doi:10.1007/s11096-005-4213-4

Cited by 80 publications

(55 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The simplest model defines polypharmacy as the use of ‡2 medications [11]. In contrast, many relevant works define polypharmacy as the prescription of ‡6 drugs [12,[18][19][20]. In our study, we used the latter threshold.…”

Section: Discussionmentioning

confidence: 99%

Polypharmacy in elderly hospitalised patients in Slovakia

et al. 2007

View full text Add to dashboard Cite

Our study confirmed a relatively high prevalence of polypharmacy in Slovak elderly patients. Polypharmacy risk rose especially with the increased prevalence of diseases of advancing age (diabetes mellitus, heart failure, arterial hypertension, dementia and cerebrovascular diseases). The increasing numbers of medications in inpatients indicate the need for the careful re-evaluation of pharmacotherapy during the stay in hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

Polypharmacy in elderly hospitalised patients in Slovakia

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Some studies [106,107] have shown that pharmacists can help to assess and prevent potential drug-related problems, but further data are necessary.…”

Section: Polypharmacy Compliance and Drug Averse Events In The Elderlymentioning

confidence: 99%

Do We Need Different Treatments for Very Elderly COPD Patients?

Valente¹,

Pasciuto²,

Bernabei³

et al. 2010

Respiration

View full text Add to dashboard Cite

Population ageing is a new challenge for physicians because of the clinical complexity of the elderly. Although geriatric pharmacology is an emerging issue, very little is known and the choice of different treatments for the very elderly is still an important question. Chronic obstructive pulmonary disease is one of the most common chronic diseases throughout the world affecting prevalently older people. Despite the increasing burden of chronic obstructive pulmonary disease in older people, underdiagnosis and undertreatment in this age group are still common problems. Some patients are frail as they have impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve. Pharmacotherapeutic decisions should be combined with a careful assessment of comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and nonadherence to treatment. There are few studies that specifically examine age as a factor influencing the pharmacokinetics and pharmacodynamics of inhaled therapies, the cornerstone of treatment for chronic obstructive pulmonary disease. This review provides a summary of age-related physiological changes and their impact on pharmacokinetics and pharmacodynamics, with particular regard to the drugs implicated in chronic obstructive pulmonary disease treatment, in order to optimize drug therapy.

show abstract

“…Pharmacists, as drug experts, should take up their responsibility of detecting and preventing DRPs, if they wish to claim a role in DRP assessment. 30 The increased knowledge following the interactive CE course did not appear to have a long-lasting effect. The follow-up survey revealed that pharmacists did not remember much of the CE course.…”

Section: Discussionmentioning

confidence: 90%

Manejo de las interacciones medicamentosas con beta-bloqueantes: la formación continuada tiene impacto a corto plazo

Driesen¹,

Simoens²,

Laekeman³

2006

Pharmacy pract. (Granada Ed. impr.)

View full text Add to dashboard Cite

*There is a lack of clear guidelines regarding the management of drug-drug interactions. Objective: To assess the impact of an educational intervention on the management of drug interactions with beta-blockers. Methods: The study had a controlled before-andafter design. The intervention group (n=10 pharmacies) received a continuing education course and guidelines on the management of drug interactions with beta-blockers. The control group (n=10 pharmacies) received no intervention. Pharmacy students and staff of internship pharmacies participated in this study. Before and after the intervention, students registered interactions with beta-blockers during two weeks. Information was obtained on drug information of the beta-blocker and the interacting drug, patient's demographics, and the mode of transaction. Results: A total number of 288 interactions were detected during both study periods. Most betablockers causing an interaction were prescribed for hypertension, and interacted with hypoglycemic agents, NSAIDs, or beta2-agonists. Pharmacists' intervention rate was low (14% in the pre-test compared to 39% in the post-test), but increased significantly in the post-test in the intervention group. Reasons for overriding the interaction included limited clinical relevance, refill prescriptions, not being aware of the interaction, and communication problems with the prescriber. Conclusion: An interactive continuing education course, during which practice-oriented guidelines were offered, affected pharmacists' short-term behavior at the counter in dealing with interactions of beta-blockers. Continuing education plays a role in raising pharmacists' awareness and responsibility towards the detection and management of drug interactions in the pharmacy.

show abstract

Identification of Potential Drug-related Problems in the Elderly: The Role of the Community Pharmacist

Cited by 80 publications

References 31 publications

Polypharmacy in elderly hospitalised patients in Slovakia

Polypharmacy in elderly hospitalised patients in Slovakia

Do We Need Different Treatments for Very Elderly COPD Patients?

Manejo de las interacciones medicamentosas con beta-bloqueantes: la formación continuada tiene impacto a corto plazo

Contact Info

Product

Resources

About